Bellicum Pharmaceuticals, Inc. (BLCM) financial statements (2021 and earlier)

Company profile

Business Address 3730 KIRBY DRIVE
HOUSTON, TX 77098
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments359193393370
Cash and cash equivalents359144393370
Short-term investments  49   
Restricted cash and investments23    
Assets held-for-sale, not part of disposal group217    
Other undisclosed current assets112637227
Total current assets:391129510210697
Noncurrent Assets
Operating lease, right-of-use asset11
Property, plant and equipment032126177
Long-term investments and receivables   1 56
Long-term investments   1 56
Restricted cash and investments  5610 
Other noncurrent assets010000
Total noncurrent assets:1426342664
TOTAL ASSETS:41116122136132160
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:4101210137
Accounts payable  4342
Accrued liabilities  9695
Employee-related liabilities12    
Other undisclosed accounts payable and accrued liabilities38    
Debt 110020
Deferred rent credit  0
Derivative instruments and hedges, liabilities1052    
Deferred revenue and credits200
Contract with customer, liability3
Other undisclosed current liabilities1021    
Total current liabilities:25941612157
Noncurrent Liabilities
Long-term debt and lease obligation 26363500
Long-term debt, excluding current maturities 263635  
Capital lease obligations0000
Liabilities, other than long-term debt  1421
Deferred revenue and credits421
Deferred rent credit  1
Other undisclosed noncurrent liabilities01  18 
Total noncurrent liabilities:0273739201
Total liabilities:251215351358
Temporary equity, carrying amount1821    
Stockholders' equity
Stockholders' equity attributable to parent(2)(26)688597152
Common stock010000
Treasury stock, value(5)(5)(5)(5)(5)(5)
Additional paid in capital544512494412332319
Accumulated other comprehensive income (loss)(0)(0)(0)(0)0(0)
Accumulated deficit(541)(533)(421)(323)(231)(161)
Total stockholders' equity:(2)(26)688597152
TOTAL LIABILITIES AND EQUITY:41116122136132160

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues272000
Revenue, net000
Net investment income 12   
Other operating income2     
Cost of revenue
(Cost of Goods and Services Sold)
  (0) (1)(3)
Gross profit:2710(0)(3)
Operating expenses(55)(95)(97)(88)(69)(49)
Other undisclosed operating income (loss)1 (0) 13
Operating loss:(52)(87)(95)(87)(68)(49)
Nonoperating income (expense)44(25)(3)(4)(1)1
Interest and debt expense0(4)(4)(2)(2)(0)
Net loss:(8)(117)(102)(94)(71)(49)
Other undisclosed net income (loss) attributable to parent(0)44220
Net loss available to common stockholders, diluted:(8)(112)(98)(92)(69)(49)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(8)(117)(102)(94)(71)(49)
Other comprehensive loss (113)(98)(92)(69)(49)
Comprehensive loss:(8)(229)(200)(185)(140)(97)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)117102947149
Comprehensive loss, net of tax, attributable to parent:(8)(113)(98)(92)(69)(49)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: